No abstract

Gloriosa superba L. (Liliaceae) is an important medicinal herb of Asia and Africa. The plant is used to cure ulcers, piles, cancer, gout, scrofula and act as abortifacient, anthelmintic, antipyretic and antiinflammatory drug. The main aim of the proposed work is to evaluate the anti-inflammatory activity of G. superba and also conserve the same plant through the in vitro propagation. The anti-inflammatory activity was evaluated by cycloxygenase inhibition assay and 5-lipoxygenase inhibition assay. In the cycloxygenase inhibition assay, the percentage inhibition were found to be 3.38%, 26.27%, 43.22% for sample concentration 100µg/ml, 500µg/ml, 1000µg/ml respectively and in the lipoxygenase inhibition assay percentage inhibition were found to be 49.23%, 76.92%, 84.61% for sample concentration 100µg/ml, 500µg/ml, 1000µg/ml respectively. In lipoxygenase inhibition assay the methanol extract of G. superba tuber showed close percentage inhibition with that of the standard aspirin. The present study thus confirmed that methanol extract of root tubers of G. superba possessed good anti-inflammatory activity. At present, the plant is on the way of extinction due to its misuse, over exploitation and unscientific collection. Micro propagation is an important method to conserve this highly antiinflammatory medicinal plant. In vitro studies of G. superba includes induction of callusing and organogenesis, using various explants. The results indicated that medium supplemented (MS) with auxin (NAA) (0.15 mg/l) and Benzylamino purine (BAP) (0.25 mg/l) induced callusing, with 2,4-D (0.5 mg/l) and Kinetin (0.25 mg/l) induced somatic embryogenesis, NAA (0. 5mg/l) and BAP (0.25 mg/l) promoted the formation of the maximum number of shooting and with NAA (0.25 mg/l) and BAP (0.15 mg/l) rooting was induced. Micro propagation will be helpful for the conservation and maximum utilization of this plant with high antiinflamatory potential along with the identification and isolation of useful bioactive molecules.

Abstract-

Objective: Tapentadol Hydrochloride was approved (November 2008) by the United States Food and Drug Administration for the relief of moderate to severe pain. It is an opioid analgesic, acts by dual mechanism as opioid receptor agonist and norepinephrine reuptake inhibitor. The present research work was aimed to develop an accurate, precise, and rapid RP-HPLC method and subsequently validates the method according to the International Conference on Harmonization (ICH) guidelines for the determination of Tapentadol Hydrochloride. Methods: Tapentadol Hydrochloride was analyzed by using High-Performance Liquid Chromatography. Better separation of the drug was achieved by using a Symmetry C18 column (150x4.6mm, 3.5μm) with the mobile phase consisted of a mixture of Orthophosphoric acid (0.1% of Orthophosphoric acid in HPLC water) and acetonitrile in the ratio of 30:70 v/v at a flow rate of 1 ml/min, and the detection was at the wavelength of 219nm using a PDA detector. Results: The retention time of Tapentadol Hydrochloride was found to be 3.747 ± 0.127 min. The method was found to be linear in the range of 10-200 ug/ml with a correlation coefficient (r2) of 0.9991. The LOD and LOQ of the method were calculated to be 0.1 and 1μg/ml respectively. The method precision and system precision was estimated and the results were calculated as % RSD values, which were found to be within the limits. Recovery of Tapentadol Hydrochloride was found to be 100.1%, which confirms the efficiency of the method. Conclusion: The developed RP-HPLC method was validated using standard ICH guidelines. The developed method can be used for the analysis of both tapentadol hydrochloride bulk and formulations.